secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001724521-25-000109
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%
-----------------------------------------------------------------

- Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.
- Confirmed ORR 59% (24/41) per RECIST v1.1; 62% in PD-L1 positive and 69% in PD-L1 high subgroups.
- Median PFS 12.9 months overall; 24-month OS rate 50.2% and PFS rate 25.9%.
- Median follow-up 26.4 months; median time on domvanalimab+zimberelimab+chemo was 49 weeks.
- No unexpected safety signals; immune-mediated TEAEs in 22% of patients, infusions reactions in 7%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000109/0001724521-25-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000109/rcus-20251012.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer